Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide in Bardet-Biedl and Alström Syndromes
NCT03746522Phase 3Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Nov 2020
- Modality
- Peptides, Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of setmelanotide in Bardet–Biedl syndrome (BBS), Alström syndrome (ALMS), sponsored by Rhythm Pharmaceuticals. Started Nov 2018; status: completed.
02
Drugs
setmelanotide
03
Conditions
Bardet–Biedl syndrome (BBS)Alström syndrome (ALMS)
Beyond the preview
Go deeper on NCT03746522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03746522.